Targeting agent antibody conjugates and uses thereof

A compound of Formula XII:

• Y-L-A1-L1-A2-L2-A3-L3-X2 (Formula XII)
• wherein:
• Y is a ligand of prostate specific membrane antigen (PSMA);
• L is
• A1 is selected from the group consisting of an aryl, a 5- to 6-membered heteroaryl, —C(O)—, —N(R1)—, —O—, —C(O)N(R1)—, —N(R1)C(O)—, —S(O)N(R1)—, —S(O)2N(R1)—, —N(R1)S(O)— and —N(R1)S(O)2—;
• L1 is
• A2 is selected from the group consisting of a bond, —C(O)—, —N(R1)—, —O—, —C(O)N(R1)—, —N(R1)C(O)—, —S(O)N(R1)—, —S(O)2N(R1)—, —N(R1)S(O)— and —N(R1)S(O)2—;
• L2 is
• A3 is a bond,
• L3 is
• X2 is a linker bound to a functional group that reacts with an unnatural amino acid, or a linker bound to a modified unnatural amino acid, wherein the modified unnatural amino acid is part of X, wherein X is a modified therapeutic peptide, protein, or antibody;
• each R1 is independently selected from H, alkyl, or haloalkyl;
• each R2, R21, R22, and R23 is independently selected from H, halo, —OR1, —CN, —SR1, alkyl, cycloalkyl, haloalkyl, arylalkyl, or heteroarylalkyl;
• each R3 is independently selected from halo, —OR1, —CN, —SR1, alkyl, cycloalkyl, haloalkyl, arylalkyl, or heteroarylalkyl, —NO2, and NR1R1;
• each G1 and G2 is independently selected from the group consisting of a bond, —C(O)—, —N(R1)—, —O—, —C(O)N(R1)—, —N(R1)C(O)—, —S(O)N(R1)—, —S(O)2N(R1)—, —N(R1)S(O)— and —N(R1)S(O)2—;
• each Z, Z1, Z2, and Z3 is independently selected from the group consisting of a bond, —O—, and —N(R1)—;
• k, k1, k2 and k3 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
• m1, m2 and m3 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
• and
• p is 0, 1, 2, 3 or 4,
• or a stereoisomer thereof.